Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference113 articles.
1. Mogle BT, Steele JM, Thomas SJ, Bohan KH, Kufel WD. Clinical review of delafloxacin: a novel anionic fluoroquinolone. J Antimicrob Chemother. 2018;73(6):1439–51.
2. Melinta Therapeutics Inc. Baxdela® (delafloxacin) product package insert. Lincolnshire: Melinta Therapeutics Inc; 2017.
3. Van Bambeke F. Delafloxacin, a non-zwitterionic fluoroquinolone in phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol. 2015;10(7):1111–23.
4. Melinta Therapeutics Inc. BAXDELA® package insert Lincolnshire, Illinois; 2019. Available from: https://baxdela.com/docs/baxdela-prescribing-information.pdf. Accessed 12 Nov 2019.
5. O’Riordan W, Mehra P, Manos P, Kingsley J, Lawrence L, Cammarata S. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2015;30:67–73.
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献